Form 4: Biogen Executive Nicole Murphy Reports Stock Transactions
SEC Form 4 Filing
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On February 10, 2025, Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reported transactions involving Biogen common stock.
- These transactions included the vesting of 2,272 restricted stock units and the withholding of 670 shares to cover tax obligations.
- Following these transactions, Murphy directly owns 14,055.3741 shares of Biogen common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, neither particularly positive nor negative.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies like Biogen. These transactions are part of standard compensation packages that include stock options and restricted stock units to align executive interests with shareholder value.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
- Employees may be interested in the details of executive compensation as a benchmark.
Key Dates
| Date | Description |
|---|---|
| 02/10/2022 | Grant date of the restricted stock units, which vest in three equal yearly installments beginning on the first anniversary of this date. |
| 02/10/2025 | Date of the reported transactions: vesting of restricted stock units and tax withholding. |
| 02/12/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, BIIB, Biogen, Stock Options, Restricted Stock Units, Insider Trading, Nicole Murphy, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.